HIGHER SABA USE IS ASSOCIATED WITH ADVERSE CLINICAL OUTCOMES: RESULTS FROM A SURVEY IN MEXICAN PHARMACIES.

Clinical Research Results Abstract HIGHER SABA USE IS ASSOCIATED WITH ADVERSE CLINICAL OUTCOMES: RESULTS FROM A SURVEY IN MEXICAN PHARMACIES. Nora E. Martínez Aguilar MDPhD, R.Ramsés Hernández Pliego MD, Janwillem WH Kocks MDPhD, Giulia RicciardeloABSTRACTGINA no longer recommends SABA(short-acting beta agonist) alone in asthma treatment, because SABA-only treatment increases the risk of severe exacerbations and death. It is important to determine of inhaled SABA in order to plan strategies that promote better asthma treatment and control. In Mexico, SABA could be obtained without prescription at pharmacies. It is currently unknown what the patterns of SABA consumption is in Mexico.Objective. Identify patterns of SABA consumption.Methods. Adults(age>18) patients with a purchasing inhaled medication from drugstores were requested to answer a questionnaire with 7 questions regarding the last 12 months. Surveys were sent by e-mail. A descriptive data analysis was carried out. Continuous variables were characterized by central and dispersion measurement parameters. Given it is an observational study, no prior calculation of the sample size was performed. Results. 385 people answered the questions, 232 were selected, 5 did not meet inclusion age criteria, 153 were excluded as they did not buy the SABA for themselves or indicated they did not have asthma. 59%female. 68.1% used SABA as rescue medication, 26% without medical follow up. 40% used SABA as their only asthma medication. 10.34% took>8 inhalations/day. 60% had asthma symptoms. 56.91% used>3 devices/year, 8.62%>12.Discussion. Mexican asthmatic patients who bought SABA at the pharmacy were not controlled:68% use SABA as rescue medication, 40% use SABA alone.26% had no medical follow up, 56.91% use>3 devices/year.62% use≥12 canisters/year, they have higher risk of death.As it is known that higher use of SABA is associated with adverse clinical outcomes. It is necessary to increase educational techniques in asthma control in Mexican pharmacies/drugstores. Research Idea Abstract Service Development & Evaluation Abstract Declaration of Interest Declaration of interest this work and the economic support was carried out with the support of AstraZeneca Mexico References and Clinical Trial Registry Information 1) GINA 2019, 2) GINA 2021. 3) Stanford RH, et al. Ann Allergy Asthma Immunol.2012;109(6):403-7. 4) Nwaru BI, et al. Eur Respir J. 2020;55(4):1901872. 5) Suissa S, et al. Am J Respir Crit Care Med. 1994;149(3 Pt 1):604-10.